需要进行类泛素化修饰：葡萄膜黑色素瘤中实现 NED 的关键。
The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.
机构信息
Division of Hematology/Oncology, Columbia University Medical Center, New York, New York.
Department of Immuno-Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.
出版信息
Clin Cancer Res. 2018 Aug 1;24(15):3477-3479. doi: 10.1158/1078-0432.CCR-18-0020. Epub 2018 Apr 2.
Abstract
The ability of uveal melanoma cells to enter and exit dormancy plays a fundamental role in the development of metastatic disease. Neddylation blockade is a promising strategy to prolong tumor dormancy via impaired angiogenesis and prevent the establishment of metastases via elimination of cancer stem-like cells. .
摘要
葡萄膜黑素瘤细胞进入和退出休眠的能力在转移性疾病的发展中起着根本性的作用。通过抑制血管生成和消除癌症干细胞样细胞来阻止转移的建立，泛素化阻断是一种延长肿瘤休眠时间的很有前途的策略。
相似文献
1
The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.需要进行类泛素化修饰：葡萄膜黑色素瘤中实现 NED 的关键。
Clin Cancer Res. 2018 Aug 1;24(15):3477-3479. doi: 10.1158/1078-0432.CCR-18-0020. Epub 2018 Apr 2.
2
Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.泛素化修饰酶抑制剂通过抑制肿瘤干细胞样细胞和血管生成减弱葡萄膜黑色素瘤肝转移
Clin Cancer Res. 2018 Aug 1;24(15):3741-3754. doi: 10.1158/1078-0432.CCR-17-1703. Epub 2017 Dec 12.
3
Modeling the behavior of uveal melanoma in the liver.模拟葡萄膜黑色素瘤在肝脏中的行为。
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):2967-74. doi: 10.1167/iovs.06-1522.
4
Anti-angiogenic therapy in uveal melanoma.葡萄膜黑色素瘤的抗血管生成治疗
Dev Ophthalmol. 2012;49:117-136. doi: 10.1159/000329591. Epub 2011 Oct 21.
5
c-MET expression in primary and liver metastases in uveal melanoma.葡萄膜黑色素瘤原发灶及肝转移灶中的c-MET表达
Melanoma Res. 2014 Dec;24(6):617-20. doi: 10.1097/CMR.0000000000000118.
6
Molecular pathways mediating liver metastasis in patients with uveal melanoma.葡萄膜黑色素瘤患者肝转移的分子通路
Clin Cancer Res. 2008 Feb 15;14(4):951-6. doi: 10.1158/1078-0432.CCR-06-2630.
7
Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.转移性葡萄膜黑色素瘤免疫原性子集的鉴定
Clin Cancer Res. 2016 May 1;22(9):2237-49. doi: 10.1158/1078-0432.CCR-15-2294. Epub 2015 Dec 28.
8
MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.源自免疫赦免器官眼睛的MHC II类转导肿瘤细胞可启动并增强与原发性和转移性葡萄膜黑色素瘤细胞发生交叉反应的CD4(+) T淋巴细胞。
Cancer Res. 2007 May 1;67(9):4499-506. doi: 10.1158/0008-5472.CAN-06-3770.
9
The bidirectional crosstalk between metastatic uveal melanoma cells and hepatic stellate cells engenders an inflammatory microenvironment.转移性葡萄膜黑色素瘤细胞与肝星状细胞之间的双向串扰产生了炎症微环境。
Exp Eye Res. 2019 Apr;181:213-222. doi: 10.1016/j.exer.2019.02.012. Epub 2019 Feb 13.
10
Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF).肝细胞生长因子/散射因子（HGF/SF）对葡萄膜黑色素瘤相互转化表型的调控
Am J Pathol. 1998 Apr;152(4):855-63.
引用本文的文献
1
Flavokawain A Reduces Tumor-Initiating Properties and Stemness of Prostate Cancer.黄樟素A降低前列腺癌的肿瘤起始特性和干性
Front Oncol. 2022 Jul 13;12:943846. doi: 10.3389/fonc.2022.943846. eCollection 2022.
2
UBE2M Drives Hepatocellular Cancer Progression as a p53 Negative Regulator by Binding to MDM2 and Ribosomal Protein L11.UBE2M 通过与 MDM2 和核糖体蛋白 L11 结合作为 p53 负调节因子驱动肝细胞癌进展。
Cancers (Basel). 2021 Sep 29;13(19):4901. doi: 10.3390/cancers13194901.
本文引用的文献
1
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.培维莫德司他，一种首创的 NEDD8 激活酶抑制剂，与阿扎胞苷联合用于 AML 患者。
Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18.
2
Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.泛素化修饰酶抑制剂通过抑制肿瘤干细胞样细胞和血管生成减弱葡萄膜黑色素瘤肝转移
Clin Cancer Res. 2018 Aug 1;24(15):3741-3754. doi: 10.1158/1078-0432.CCR-17-1703. Epub 2017 Dec 12.
3
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.胰腺腺癌的组合筛选揭示了对包括溴结构域抑制剂加Neddylation抑制剂在内的药物组合的敏感性。
Mol Cancer Ther. 2017 Jun;16(6):1041-1053. doi: 10.1158/1535-7163.MCT-16-0794. Epub 2017 Mar 14.
4
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.一项关于研究性NEDD8激活酶抑制剂pevonedistat（TAK-924/MLN4924）用于转移性黑色素瘤患者的I期研究。
Invest New Drugs. 2016 Aug;34(4):439-49. doi: 10.1007/s10637-016-0348-5. Epub 2016 Apr 8.
5
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.新型研究性NEDD8激活酶抑制剂pevonedistat（MLN4924）用于复发/难治性多发性骨髓瘤或淋巴瘤患者的I期研究
Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.
6
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.TAK-924/MLN4924 治疗晚期实体瘤患者的 NEDD8 激活酶抑制剂的 I 期临床研究。
Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.
7
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.pevonedistat（MLN4924），一种新型的NEDD8激活酶抑制剂，用于急性髓系白血病和骨髓增生异常综合征患者：一项1期研究。
Br J Haematol. 2015 May;169(4):534-43. doi: 10.1111/bjh.13323. Epub 2015 Mar 2.
8
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.组蛋白去乙酰化酶抑制剂诱导葡萄膜黑色素瘤的生长停滞和分化。
Clin Cancer Res. 2012 Jan 15;18(2):408-16. doi: 10.1158/1078-0432.CCR-11-0946. Epub 2011 Oct 28.
9
Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy.葡萄膜黑素瘤细胞系中含有自我更新、产生分化后代并能耐受化疗的干细胞样细胞。
Invest Ophthalmol Vis Sci. 2011 Oct 31;52(11):8458-66. doi: 10.1167/iovs.11-7379.
10
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis.葡萄膜黑色素瘤的预后生物标志物：与转移相关的干细胞样表型的证据。
Melanoma Res. 2008 Jun;18(3):191-200. doi: 10.1097/CMR.0b013e3283005270.
Zotero 插件